RBRahul Bhatnagar

Rahul Bhatnagar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rahul Bhatnagar has a total of 510 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Image Quality of Handheld Ultrasound Devices for Lung Ultrasound in Adult Patients with Pneumonia

    by Simon Micheelsen Norlén, Morten H. Lorentzen, Christian B. Laursen, Rahul Bhatnagar, Stefan Posth, Søren Helbo Skaarup, Pia I. Pietersen

    Objectives: Handheld ultrasound devices (HHUDs) have increased accessibility and convenience of ultrasonography, but also raised concern regarding image quality and sufficiency for clinical use. This explorative study aims to compare image quality between 3 commercially available HHUDs in patients with pneumonia, and to compare expert agreement on image quality and sonopathological findings. Methods: Patients were scanned with 3 different HHUDs. Clips were stored, anonymized, duplicated, and randomized. Three blinded, experienced thoracic ultrasound operators independently rated the clips for image quality (1–5), sufficiency for clinical use (1–3), and presence of sonopathological findings. Results: Eleven patients were scanned, yielding 38 ultrasound clips and 76 ratings per rater. Overall image quality was 3.60 (95% CI 3.40–3.80) for Lumify , 3.32 (95% CI 3.11–3.53) for Vscan Air , and 2.78 (95% CI 2.55–3.01) for Butterfly iQ+ . Overall agreement on image quality ratings was low (27.6%). Interrater agreement for specific sonopathological findings ranged from slight for air bronchograms (kappa 0.15–0.34) to substantial for pleural effusions (kappa 0.58–0.84). Conclusion: This explorative study demonstrated a higher image quality in Vscan Air and Lumify compared to Butterfly iQ+ in patients with pneumonia. However, interrater agreement on image quality was low, while interrater agreement on sonopathological findings was moderate.


  • Open Access

    Indwelling pleural catheters with talc pleurodesis for recurrent heart failure-related pleural effusions: The REDUCE-2 feasibility randomised trial

    by Hugh Welch, Emma Tucker, Avinash Aujayeb, Kevin Conroy, Thapas Nagarajan, Rakesh Panchal, Geraldine Lynch, Alina Ionescu, Owais Kadwani, John Corcoran, et al.

    Background: Heart failure is the most common cause of pleural effusions. For patients with refractory HF-related pleural effusions (HFPE), repeated therapeutic thoracentesis (TT) is standard care. In malignant pleural effusions, indwelling pleural catheters (IPCs) combined with talc instillation improve pleurodesis rates, but their role in HFPE remains uncertain. Aims: To evaluate the feasibility of conducting a full-scale multicentre randomised trial comparing recurrent TT with IPC insertion, daily drainage, and talc instillation across 13 UK centres. Feasibility was defined a priori as achieving 80% of the target sample size (40 patients) and enrolling ≥50% of eligible patients. Methods: Adults with refractory HFPE were assessed for eligibility and randomised 1:1 to TT or IPC with daily drainage and talc. The trial was non-blinded, and participants were followed for 12 weeks. Results: Among 231 patients screened, 43 were eligible; most exclusions reflected insufficient effusion size or symptom severity, or improvement following medical optimisation. Eighteen patients (42% of those eligible) were randomised (median age 79; IQR 70–83; Clinical Frailty Score 6; IQR 5–6). Eight participants completed follow-up; five died, and five withdrew. Pleurodesis occurred in 3/8 (38%) in the IPC/talc arm and in none of the TT arm. The IPC/talc arm required fewer total pleural procedures (1.0 versus 2.0; p<0.001) but experienced a higher complication rate. Conclusions: Feasibility targets were not met. Improvements in medical management may have reduced the need for invasive treatment of HFPE, with many screened patients responding to medical therapy alone. Further challenges to recruitment included the elderly, polymorbid and frail nature of the cohort.

  • Open Access

    Needle aspiration versus intercostal chest drain for secondary spontaneous pneumothorax (the PRINCE-SSP trial): a pragmatic, open-label, multi-centre, non-inferiority, randomised controlled trial

    by Steven Walker, Siobhan Creanor, Edward Carlton, Eleanor Taylor, Heather Cook, Ella Chaudhuri, James Connors, Ramon Luengo-Fernandez, Adam Palmer-Welsh, Svetlana Ratushnyak, et al.

  • Open Access

    Qualitative insights into patient and carer perspectives of malignant pleural effusion management: an embedded study within the TACTIC trial

    by Alice Milne, Alexandra Dipper, Rahul Bhatnagar, Anand Sundaralingam, Najib M Rahman, Nick Maskell, Andrew J Moore

    Background: Malignant pleural effusion (MPE) is a condition characterised by excessive fluid build-up in the pleural cavity caused by cancer. Management options focus on drainage of fluid from the pleural cavity with a common aim of minimising symptoms and improving quality of life. Definitive pleural intervention is recommended for most patients with MPE to achieve longer-term symptom control. A patient-centred approach is also emphasised. However, little is known about the patient and carer experiences of MPE management. Therefore, this study sought to examine patient and carer experiences of differing procedural interventions within a trial setting. Methods: Patients with MPE and their carers who were taking part in the TACTIC trial in hospitals across the UK were invited to take part in a one-off interview. Thirty-two participants were recruited, and 22 semistructured interviews were conducted. Interview formats were either patient only, carer only or patient and carer dyad interviews. Interviews were audio recorded, transcribed verbatim and analysed using a generalised thematic analysis approach. Results: Initial findings demonstrated that patients and carers were generally satisfied with the MPE management and care received. No significant differences in acceptability were found between the two management strategies. Further analysis led to the development of four overarching themes: experiences of MPE beyond the trial, experiences of pain, preferences in MPE care and measuring MPE: rethinking patient relevance. These findings underscore the importance of greater consideration of pain management during MPE care, as well as improved communication and information prior to procedures. Conclusion: Patients and carers found the TACTIC combined procedure tolerable and acceptable. Echoing the growing evidence of research in this field, authors emphasise the importance of outcome measure selection in MPE trials and suggest a need for a Core Outcome Set to establish fundamental priorities in MPE management.

  • Open Access

    Aetiology, management, and outcomes of eosinophilic pleural effusion: data from the International Multicentre Pleural Research Collaborative

    by Rafal Krenke, Magdalena E. Grabczak, Jordy Kerkhoff, Silvia Bielsa, José M. Porcel, Mateja Marc-Malovrh, Ales Rozman, Michael A. Mitchell, Katarzyna Faber, Stavros Anevlavis, et al.

    Background: Eosinophilic pleural effusion (EPE) is a relatively uncommon condition. The objective of this study was to evaluate the clinical, laboratory, and radiological features of EPE in a multicentre cohort of patients. Methods: This retrospective study included patients with EPE, defined as pleural fluid in which eosinophils constitute ≥10% of the total nucleated cell count, treated between 2009 and 2021 at eight respiratory centres. Predefined data were collected in the International Multicentre Pleural Research Collaborative (IMPACT) registry. Results: The study included 210 patients (144 [68.6%] males), with a median age of 67 years (IQR 55–78). Radiological evaluation showed unilateral effusion in 194 (94.2%) patients. Most EPEs (199; 95.7%) were exudates. The median pleural fluid eosinophil percentage was 23% (IQR 14.8–43.3%). The most common aetiologies were malignancy 61 (29%), infection 43 (20.5%), heart diseases/cardiac intervention 17 (8.1%), or trauma 16 (7.6%). In 42 (20%) patients, the cause of EPE remained undetermined. In univariate and multivariable analyses incorporating available clinical and laboratory data, EPE was not a significant predictor of either malignancy or benign disease. Conclusion: Eosinophilic pleural effusion is a non-specific diagnostic entity and should not, by itself, be regarded as a relevant factor in clinical decision-making.


  • Open Access

    Reply: Optimal follow-up duration for nonspecific pleuritis: how long is long enough?

    by Anand Sundaralingam, Rahul Bhatnagar

    We welcome your correspondence “Optimal follow-up duration for nonspecific pleuritis: how long is long enough?”, submitted in response to our article “Investigation and outcomes in patients with non-specific pleuritis: results from the International Collaborative Effusion Database” [1].

  • Open Access

    Ki67 proliferation index augments two-tier tumour grade in prediction of survival and progression-free survival in epithelioid pleural mesothelioma

    by Geraldine A. Lynch, Yu Zhi Zhang, Nidhi Bhatt, Pia Charters, Avinash Aujayeb, Saru Walker, Jenny Symonds, Amelia O. Clive, Rahul Bhatnagar, Anna Morley, et al.

    Background: Pleural mesothelioma (PM) is a fatal asbestos-related cancer with a poor and often uncertain prognosis. This study validates the histological proliferation marker Ki67 and evaluates whether its integration into the two-tier tumour grading system can improve prognostication in epithelioid PM. Methods: Patients with epithelioid PM were recruited from two longitudinal cohort studies from 2010–2023. Diagnostic biopsies were analysed by three pulmonary pathologists. Cox regression determined the relationship between covariables and outcomes. Pearson correlation assessed the association between Ki67 and two-tier grade. A prognostic model combining Ki67 and tumour grade was internally validated using bootstrapping. Results: 98 patients were recruited. Ki67 was strongly predictive of overall survival (OS) and progression-free survival (PFS) and correlated with two-tier tumour grade. 30% was the optimal cut-off, with Ki67 more strongly predictive of OS (hazard ratio (HR) 2.37, 95% CI 1.51–3.71) and PFS (HR 2.09, 1.35–3.23) than two-tier grade (HR 1.83, 1.13–2.97 and HR 1.70, 1.08–2.66, respectively). Combining Ki67 and two-tier grade improved prediction of OS and PFS compared with two-tier grade alone. Ki67 stratified patients within each tumour grade, with median survival in the lowest risk group (low Ki67, low grade) of 660.5 days (IQR 329–1297) and 300 days (IQR 124–366) in the highest risk group (high Ki67, high grade). Conclusion: Ki67 is a valid surrogate for tumour grade with an optimal cut-off at 30%. Integrating Ki67 into the two-tier grading system enhances prognostic accuracy, improves outcome prediction and would reduce uncertainty for patients and clinicians.

  • Open Access

    First-line medical thoracoscopy for pleural infection: the SPIRIT randomised controlled feasibility trial

    by Krishan Ragab Bansal, David T Arnold, Emma Tucker, Anna Morley, Liju Ahmed, Hugh Ip, Parthipan Sivakumar, Henry Steer, Matthew Evison, Najib Rahman, et al.

    Background: Pleural infection remains a significant clinical challenge, requiring hospitalisation, intravenous antibiotics and early chest drain insertion. Medical thoracoscopy (MT), a minimally invasive procedure used electively in the UK for malignant effusions, has demonstrated good outcomes when applied to acute pleural infection in retrospective case series. However, it has not been evaluated as a first-line intervention in the UK in a randomised controlled trial (RCT). Objectives: The Studying Pleuroscopy in Routine Pleural Infection Treatment (SPIRIT) trial assessed the feasibility of conducting a full-scale RCT comparing MT with chest drain insertion for acute pleural infection within UK National Health Service (NHS) hospitals. Methods: SPIRIT was an open-label, randomised feasibility trial conducted across seven NHS centres between 2017 and 2019. Adults with suspected pleural infection were prescreened; eligible patients were randomised to either chest drain insertion (control) or MT (performed the same or following day) with 90-day follow-up. The primary outcome was feasibility, assessed through a composite of prescreen, screen and allocation failure rates. Secondary outcomes included inpatient-stay duration, mortality, radiological and microbiological outcomes, second-line interventions, patient-reported outcomes and adverse events. Results: Of 193 patients prescreened, 181 (93.8%) were excluded due to at least one criterion. Key factors included lack of MT deliverability (49.2%), a not truly infected effusion (45.1%) and contraindications to drainage or study involvement (44.0%). Consequently, the primary feasibility endpoint was not met. All 12 eligible patients were randomised with no attrition. MT lasted 15 min longer than drain insertion, but chest drains remained in situ over 3 days longer (p=0.17) with a longer hospital stay (p=0.57). Radiological improvement, microbiological yield and symptom scores were similar. Adverse events occurred in one control and three MT patients. Conclusion: A full-scale RCT is not likely to be feasible in an NHS setting on the proposed protocol. Targeted recruitment from centres equipped for emergency MT may enhance feasibility. Trial registration number: ISRCTN98460319 .


  • Open Access

    Characteristics and predictors of clinical outcome in patients with pleural effusions caused by heart, liver and renal failure: results from the ERS International Multicentre Pleural Research Collaborative (IMPACT) registry

    by Hugh Welch, Steven Walker, Jordy Kerkhoff, Julius Janssen, Silvia Bielsa, Carmen Civit, Jose M. Porcel, Katrine Fjaellegaard, Jesper Petersen, Uffe Bodtger, et al.

    Introduction: Pleural effusions caused by organ dysfunction are the commonest pleural disease and account for a huge healthcare burden. Previous work has demonstrated poor survival rates, but there is still uncertainty about determinants of prognosis. This study describes the characteristics and risk factors for poor outcomes in patients with pleural effusion secondary to organ failure in an international cohort. Methods: The European Respiratory Society International Multicentre Pleural Research Collaborative (IMPACT) registry includes an international retrospective study of patients with effusions secondary to heart, liver or renal failure, collected from 10 countries in Europe and North and South America between 2019 and 2021. The data were analysed for associations between baseline patient characteristics and key clinical outcomes. Descriptive data were collected on treatments and complications. Results: A total of 755 patients contributed data. Overall, 85.2% of effusions were classified as transudates by Light's criteria. 42% of effusions were bilateral. One-year mortality rates were 46% in renal, 35% in hepatic and 33% in cardiac effusions. Increased mortality was observed in neutrophil-predominant effusions (HR 2.001, 95% CI 1.202–3.349, p=0.008), with age (HR 1.013, 95 CI 1.002–1.024, p=0.02) and with N-terminal pro-brain natriuretic peptide >450 pg·mL −1 (HR 1.508, 95% CI 1.191–1.911) in patients with cardiac failure. Therapeutic thoracentesis was the most frequently employed pleural intervention; indwelling pleural catheter use was rare and associated with higher pleural infection rates than thoracentesis. Conclusion: This study identifies prognostic factors in an international cohort of patients with transudative pleural effusions. Identification of these risk factors may support treatment approaches in a global population.


  • Local Anaesthetic Thoracoscopy Practice in the UK in 2024: A Snapshot Survey

    by Richard Westley, Avinash Aujayeb, Rahul Bhatnagar, Duneesha De Fonseka

    Introduction: Local anaesthetic thoracoscopy (LAT) is widely available in the UK. It is often the investigation of choice for unexplained exudative pleural effusions. There are no agreed national standards regarding LAT, with many sites following locally developed guidelines. The last survey of UK practice was in 2017. Methods: An electronic survey was circulated to UK Pleural Society (UKPS) members and through direct communication with centres known to be undertaking LAT. Invited centres were requested to distribute the survey further. Results: Thirty-seven responses were included. LAT remains the preferred investigation for an undiagnosed exudative pleural effusion (32/37, 87%). The number of trained thoracoscopists ranged from 1 to 6. Thirty centres (81%) had dedicated thoracoscopy lists with varying frequency. Nineteen (51%) centres routinely admitted patients post-thoracoscopy (compared to 76% in 2017). Thirty centres (81%) did not routinely administer antibiotics. Thirty-five centres (95%) routinely used sedation, the commonest agent being midazolam, typically in combination with an opiate. Eleven centres (30%) utilised other pre-medications, while 8/37 (22%) of centres administered intravenous fluids. Where a minimal effusion is present 27/37 (73%) would induce a pneumothorax. Eleven (29%) centres would perform LAT for pleural infection. Only 11/37 (30%) of centres have on-site thoracic surgical support. Conclusions: There is wide variation in LAT practice among UK centres. These results support the need for identifying best practice and standardisation of LAT practices, with outcome reporting. These survey results will form the basis of applications to the national and international respiratory societies to develop relevant standards.